Literature DB >> 27625918

Moving upwards - the journal of cachexia, sarcopenia and muscle in 2016.

Stephan von Haehling1, Nicole Ebner1, Stefan D Anker1.   

Abstract

Entities:  

Year:  2016        PMID: 27625918      PMCID: PMC5011813          DOI: 10.1002/jcsm.12142

Source DB:  PubMed          Journal:  J Cachexia Sarcopenia Muscle        ISSN: 2190-5991            Impact factor:   12.910


× No keyword cloud information.
The good news first, the Journal of Cachexia, Sarcopenia and Muscle (JCSM) has not only maintained its impact factor, but it has even increased it again, now reaching 7.883 as has been published by Thomson Scientific a few weeks ago. This places JCSM again as the number 9 ranked journal amongst all journals in ‘Medicine, General and Internal’ (Table 1) and as number 2 ranking publication amongst all nutrition journals, amongst which; however, JCSM is still not offficially listed by Thomson Scientific (Table 2). This new impact factor re‐confirms the inaugural impact factors of 7.413 for 2013 and 7.315 for 2014. As before, we would like to sincerely thank all authors, reviewers and editorial board members for their great efforts to produce JCSM at good quality, and we greatly appreciate and value also the interest and support of all those who enjoy reading JCSM and cite the papers published there.
Table 1

Top ten journals in the field ‘Medicine: General & Internal’, adapted from reference 1

Journal nameImpact factor 2016Items published in 2014 & 2015
1New England journal of medicine59.558701
2Lancet44.002547
3Journal of the American medical association (JAMA)37.684449
4British medical journal19.697519
5Annals of internal medicine16.440325
6JAMA internal medicine14.000332
7PLOS medicine13.585246
8BMC medicine8.005379
9Jounal of cachexia sarcopenia and muscle7.88360
10Journal of internal medicine7.803198
Table 2

Top ten journals in the field ‘Nutrition & Dietetics’, where the journal of cachexia, sarcopenia and muscle is officially not listed

Journal nameImpact factor 2016 Items published in 2014 & 2015
1Progress in lipid research11.23863
2Annuals review of nutrition6.78437
3American journal of clinical nutrition6.703671
4Nutrition reviews5.591149
5Critical reviews in food science and nutrition5.492185
6International journal of obesity5.337484
7Proceedings of the nutrition society4.703111
8Journal of nutritional biochemistry4.668398
9Advances in nutrition4.576158
10Clinical nutrition4.487318
Top ten journals in the field ‘Medicine: General & Internal’, adapted from reference 1 Top ten journals in the field ‘Nutrition & Dietetics’, where the journal of cachexia, sarcopenia and muscle is officially not listed This year is special for JCSM for several reasons. One is the publication of an additional (5th) issue in May this year, the other the launch dedicated daughter journals. Indeed, JCSM appears to have sparked more scientific interest in the field of body wasting, cachexia and sarcopenia; and thus, the number of submissions to the main journal remains on the increase. With a 78% rejection rate – knowing that we have to decline publication of many good papers, simply for lack of space – we hope to be able to give some of these a home in our new daughter journals – JCSM Rapid Communications and JCSM Clinical Reports. These journals will be published online only on an open access basis, and we hope that they will help to create a family of journals dedicated to this fascinating field of research into cachexia, sarcopenia and muscle, and that they will help in clinical decision making and in serving as a source of clinical information and case reports as well. The main journal, JCSM, at the time of this writing this editorial on 18 July 2016, the journal has received 158 submissions in 2016 alone (Figure 1). Last year at this time, we had received 106 submissions .51 Given these higher numbers of submissions, in 2017, we will move to six issues per year to allow publication of more accepted papers. If all goes well, in 2018, we could then possibly move to publication of eight issues per year.
Figure 1

Number of manuscript submissions to the Journal of Cachexia, Sarcopenia and Muscle by year of publication. *Numbers for 2016 are estimated on the number of submissions until 18 July 2016 (Reprinted from 51).

Number of manuscript submissions to the Journal of Cachexia, Sarcopenia and Muscle by year of publication. *Numbers for 2016 are estimated on the number of submissions until 18 July 2016 (Reprinted from 51). We are working hard to provide a timely peer review, which is not always easy, as it is difficult at times to find appropriate reviewers. Articles that are available for the longest time are – not surprisingly – those that have been cited most (Table 3). Our ‘facts and numbers’ editorials remain popular (Tables 4 and 5), and we invite our readers to submit their work or to suggest topics for ‘facts and numbers’ editorials that are relevant to our readers.
Table 3

Top twenty of best cited articles since first publication of the journal of cachexia, sarcopenia and muscle

First authorTitleTypeYearTimes citedReference
1.von HaehlingCachexia as a major underestimated and unmet medical need: facts and numbersEditorial2010181 2
2.von HaehlingAn overview of sarcopenia: facts and numbers on prevalence and clinical impactEditorial201094 3
3.DaltonThe selective androgen receptor modulator GTx‐024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double‐blind, placebo‐controlled phase II trialOriginal Article201188 4
4.LenkSkeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise trainingReview201086 5
5.MakWasting in chronic kidney diseaseReview201166 6
6.FanzaniMolecular and cellular mechanisms of skeletal muscle atrophy: an updateReview201263 7
7.ElkinaThe role of myostatin in muscle wasting: an overview.Review201163 8
8.CesariBiomarkers of sarcopenia in clinical trials‐recommendations from the International Working Group on SarcopeniaOriginal Article201260 9
9.LainscakBody mass index and prognosis in patients hospitalized with acute exacerbation of chronic obstructive pulmonary diseaseOriginal Article201155 10
10.MorleyFrom sarcopenia to frailty: a road less traveledEditorial201454 11
11.von HaehlingFrom muscle wasting to sarcopenia and myopenia: update 2012Editorial201252 12
12.LainscakThe obesity paradox in chronic disease: facts and numbersEditorial201244 13
13.PatelSerum creatinine as a marker of muscle mass in chronic kidney disease: results of a cross‐sectional study and review of literatureReview201343 14
14.FearonMyopenia‐a new universal term for muscle wastingEditorial201143 15
15.SakumaSarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle massReview201242 16
16.SchefoldIntensive care unit‐acquired weakness (ICUAW) and muscle wasting in critically ill patients with severe sepsis and septic shockReview201041 17
17.BusquetsMyostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performanceOriginal Article201239 18
18.WakabayashiRehabilitation nutrition for sarcopenia with disability: a combination of both rehabilitation and nutrition care managementReview201437 19
19.FarkasCachexia as a major public health problem: frequent, costly, and deadlyReview201337 20
20.RozentrytThe effects of a high‐caloric protein‐rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double‐blind pilot studyOriginal Article201035 21
Table 4

Top twenty of best cited articles published 2014 in the journal of cachexia, sarcopenia and muscle

First authorTitleTypeYearTimes citedReference
1.MorleyFrom sarcopenia to frailty: a road less traveledEditorial201454 11
2.WakabayashiRehabilitation nutrition for sarcopenia with disability: a combination of both rehabilitation and nutrition care managementReview201437 19
3.von HaehlingPrevalence, incidence and clinical impact of cachexia: facts and numbers‐update 2014Editorial201429 22
4.MorleyAre we closer to having drugs to treat muscle wasting disease?Editorial201426 23
5.AnkerMuscle wasting disease: a proposal for a new disease classificationEditorial201424 24
6.EbnerHighlights from the 7th Cachexia Conference: muscle wasting pathophysiological detection and novel treatment strategiesMeeting Report201423 25
7.HeymsfieldAssessing skeletal muscle mass: historical overview and state of the artReview201421 26
8.PietraAnamorelin HCI (ONO‐7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia‐cachexia syndrome: preclinical profileOriginal Article201420 27
9.MorleyPrevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology‐update 2014Editorial201417 28
10.FragalaBiomarkers of muscle quality: N‐terminal propeptide of type III procollagen and C‐terminal agrin fragment responses to resistance exercise training in older adultsOriginal Article201415 29
11.ToledoFormoterol in the treatment of experimental cancer cachexia: effects on heart functionOriginal Article201413 30
12.RheeResistance exercise: an effective strategy to reverse muscle wasting in hemodialysis patients?Editorial201412 31
13.ArgilesCachexia: a problem of energetic inefficiencyReview201411 32
14.PoetschThe anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old ratsOriginal Article201411 33
15.HenwoodAssessing sarcopenic prevalence and risk factors in residential aged care: methodology and feasibilityOriginal Article201410 34
16.OrmsbeeOsteosarcopenic obesity: the role of bone, muscle, and fat on healthReview201410 35
17.AlchinSarcopenia: describing rather than defining a conditionReview20149 36
18.MirzaAttenuation of muscle wasting in murine C2C12 myotubes by epigallocatechin‐3‐gallateOriginal Article20149 37
19.KirkmanAnabolic exercise in haemodialysis patients: a randomised controlled pilot studyOriginal Article20148 38
20.PalusMuscle wasting: an overview of recent developments in basic researchReview20148 39
Table 5

Top ten of the best cited articles published 2015 in the journal of cachexia, sarcopenia and muscle

First authorTitleTypeYearTimes citedReference
1.ChenGhrelin prevents tumour‐ and cisplatin‐induced muscle wasting: characterization of multiple mechanisms involvedOriginal Article20157 40
2.SassoA framework for prescription in exercise‐oncology researchEditorial20156 41
3.StephensEvaluating potential biomarkers of cachexia and survival in skeletal muscle of upper gastrointestinal cancer patientsOriginal Article20156 42
4.CalvaniBiomarkers for physical frailty and sarcopenia: state of the science and future developmentsReview20154 43
5.EzeokePathophysiology of anorexia in the cancer cachexia syndromReview20154 44
6.FearonRequest for regulatory guidance for cancer cachexia intervention trialsEditorial20154 45
7MorleyRapid screening for sarcopeniaEditorial20153 46
8.BrowenSkeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise trainingReview20154 47
9.FaberImproved body weight and performance status and reduced serum PGE(2) levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro‐esophageal junctionOriginal Article20154 48
10.TrobecInfluence of cancer cachexia on drug liver metabolism and renal elimination in ratsOriginal Article20154 49
Top twenty of best cited articles since first publication of the journal of cachexia, sarcopenia and muscle Top twenty of best cited articles published 2014 in the journal of cachexia, sarcopenia and muscle Top ten of the best cited articles published 2015 in the journal of cachexia, sarcopenia and muscle Finally, we would like to draw your attention to the up‐coming Cachexia Conference, to be held on December 10–11, 2016 in Berlin, Germany. The conference now goes annually, and it has been a source of stimulating ideas and exchange between clinicians and researchers in the field of cachexia and wasting. More information can be found at the following link: http://society‐scwd.org.

Conflict of interest

None declared.
  51 in total

1.  The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial.

Authors:  James T Dalton; Kester G Barnette; Casey E Bohl; Michael L Hancock; Domingo Rodriguez; Shontelle T Dodson; Ronald A Morton; Mitchell S Steiner
Journal:  J Cachexia Sarcopenia Muscle       Date:  2011-08-02       Impact factor: 12.910

2.  Cachexia as a major underestimated and unmet medical need: facts and numbers.

Authors:  Stephan von Haehling; Stefan D Anker
Journal:  J Cachexia Sarcopenia Muscle       Date:  2010-10-26       Impact factor: 12.910

3.  An overview of sarcopenia: facts and numbers on prevalence and clinical impact.

Authors:  Stephan von Haehling; John E Morley; Stefan D Anker
Journal:  J Cachexia Sarcopenia Muscle       Date:  2010-12-17       Impact factor: 12.910

4.  Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training.

Authors:  Karsten Lenk; Gerhard Schuler; Volker Adams
Journal:  J Cachexia Sarcopenia Muscle       Date:  2010-10-26       Impact factor: 12.910

5.  Intensive care unit-acquired weakness (ICUAW) and muscle wasting in critically ill patients with severe sepsis and septic shock.

Authors:  Joerg C Schefold; Jeffrey Bierbrauer; Steffen Weber-Carstens
Journal:  J Cachexia Sarcopenia Muscle       Date:  2010-12-17       Impact factor: 12.910

6.  The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double-blind pilot study.

Authors:  Piotr Rozentryt; Stephan von Haehling; Mitja Lainscak; Jolanta U Nowak; Kamyar Kalantar-Zadeh; Lech Polonski; Stefan D Anker
Journal:  J Cachexia Sarcopenia Muscle       Date:  2010-10-26       Impact factor: 12.910

7.  The role of myostatin in muscle wasting: an overview.

Authors:  Yulia Elkina; Stephan von Haehling; Stefan D Anker; Jochen Springer
Journal:  J Cachexia Sarcopenia Muscle       Date:  2011-07-26       Impact factor: 12.910

8.  Myopenia-a new universal term for muscle wasting.

Authors:  Kenneth Fearon; William J Evans; Stefan D Anker
Journal:  J Cachexia Sarcopenia Muscle       Date:  2011-03-25       Impact factor: 12.910

9.  Body mass index and prognosis in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease.

Authors:  Mitja Lainscak; Stephan von Haehling; Wolfram Doehner; Irena Sarc; Tina Jeric; Kristina Ziherl; Mitja Kosnik; Stefan D Anker; Stanislav Suskovic
Journal:  J Cachexia Sarcopenia Muscle       Date:  2011-03-01       Impact factor: 12.910

10.  Wasting in chronic kidney disease.

Authors:  Robert H Mak; Alp T Ikizler; Csaba P Kovesdy; Dominic S Raj; Peter Stenvinkel; Kamyar Kalantar-Zadeh
Journal:  J Cachexia Sarcopenia Muscle       Date:  2011-03-16       Impact factor: 12.910

View more
  2 in total

Review 1.  Casting the net broader to confirm our imaginations: the long road to treating wasting disorders.

Authors:  Stephan von Haehling
Journal:  J Cachexia Sarcopenia Muscle       Date:  2017-12       Impact factor: 12.910

2.  Ethical guidelines for publishing in the journal of cachexia, sarcopenia and muscle: update 2017.

Authors:  Stephan von Haehling; John E Morley; Andrew J S Coats; Stefan D Anker
Journal:  J Cachexia Sarcopenia Muscle       Date:  2017-11-03       Impact factor: 12.910

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.